AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 201 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4 | -20.0% | 157 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $5 | +25.0% | 157 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $4 | 0.0% | 157 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $4 | -99.9% | 157 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $4,000 | 0.0% | 157 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $4,000 | -20.0% | 157 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $5,000 | 0.0% | 157 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $5,000 | -28.6% | 157 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $7,000 | -22.2% | 157 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $9,000 | +12.5% | 157 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $8,000 | +14.3% | 157 | 0.0% | 0.00% | +100.0% |
| Q4 2020 | $7,000 | +40.0% | 157 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $5,000 | -37.5% | 157 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $8,000 | +33.3% | 157 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $6,000 | -14.3% | 157 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $7,000 | +40.0% | 157 | 0.0% | 0.00% | +100.0% |
| Q3 2019 | $5,000 | -37.5% | 157 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $8,000 | -27.3% | 157 | 0.0% | 0.00% | -33.3% |
| Q1 2019 | $11,000 | +57.1% | 157 | 0.0% | 0.00% | +50.0% |
| Q4 2018 | $7,000 | -41.7% | 157 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $12,000 | -7.7% | 157 | 0.0% | 0.00% | -20.0% |
| Q2 2018 | $13,000 | 0.0% | 157 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $13,000 | +44.4% | 157 | 0.0% | 0.01% | +66.7% |
| Q4 2017 | $9,000 | -10.0% | 157 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $10,000 | +25.0% | 157 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $8,000 | -11.1% | 157 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $9,000 | +28.6% | 157 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $7,000 | -12.5% | 157 | 0.0% | 0.00% | -25.0% |
| Q3 2016 | $8,000 | +14.3% | 157 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $7,000 | +16.7% | 157 | 0.0% | 0.00% | +33.3% |
| Q1 2016 | $6,000 | -40.0% | 157 | 0.0% | 0.00% | -50.0% |
| Q4 2015 | $10,000 | -9.1% | 157 | 0.0% | 0.01% | -14.3% |
| Q3 2015 | $11,000 | -35.3% | 157 | 0.0% | 0.01% | -30.0% |
| Q2 2015 | $17,000 | +13.3% | 157 | 0.0% | 0.01% | +11.1% |
| Q1 2015 | $15,000 | – | 157 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |